Viewing Study NCT06361199



Ignite Creation Date: 2024-05-06 @ 8:24 PM
Last Modification Date: 2024-10-26 @ 3:26 PM
Study NCT ID: NCT06361199
Status: COMPLETED
Last Update Posted: 2024-04-19
First Post: 2024-03-12

Brief Title: Proximod Pharmacokinetics in Healthy Subjects and Patients With Rheumatoid Arthritis
Sponsor: Longevity Inc
Organization: Longevity Inc

Study Overview

Official Title: A Single-center Randomized Double-blind Placebo-controlled Phase Ib Study to Evaluate the Tolerability Pharmacokinetics and Pharmacodynamics of Proximod in Healthy Subjects and Patients With Rheumatoid Arthritis
Status: COMPLETED
Status Verified Date: 2024-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this clinical trial is to evaluate the tolerability pharmacokinetics and pharmacodynamics of Proximod in healthy subjects and patients with rheumatoid arthritis The main questions it arms to answer are

1 to evaluate the safety and tolerance of Proximod in health subjects after repeated doses
2 to assess the pharmacokinetics and pharmacodynamics of Proximod in healthy subjects after repeated doses
3 to evaluate the safety and tolerance of Proximod in patients with rheumatoid arthritis
4 to evaluate the pharmacokinetics and pharmacodynamics of Proximod in patients with rheumatoid arthritis

Participants will receive test tablets or placebo at the indicated date and collect blood samples
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None